That's PTC's (NASDAQ: PTC) raison d'etre, and the company looks set for solid growth for many years. Moreover, despite a 57% appreciation, the stock's valuation remains highly attractive for ...

Below is Validea's guru fundamental report for PTC INC (PTC). Of the 22 guru strategies we follow, PTC rates highest using our P/B Growth Investor model based on the published strategy of Partha ...

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report)’s share price rose 4.8% on Tuesday after Robert W. Baird raised their price target on the stock from $48.00 to $52.00. Robert W. Baird currently ...

JPMorgan raised the firm’s price target on PTC Therapeutics (PTCT) to $62 from $51 and keeps an Overweight rating on the shares. The firm updated the company’s model. Discover the latest ...

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) reached a new 52-week high during mid-day trading on Wednesday after Robert W. Baird raised their price target on the stock from $48.00 to $52.00 ...

Shares of PTC Inc. (NASDAQ:PTC – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the twelve brokerages that are presently covering the firm, MarketBeat.com reports. Four ...

PTC (NASDAQ:PTC) is preparing to release its quarterly earnings on Wednesday, 2024-11-06. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect PTC ...

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the design software stocks, including PTC (NASDAQ:PTC) ...

StockNews.com downgraded shares of PTC Therapeutics (NASDAQ:PTCT – Free Report) from a buy rating to a hold rating in a ...

PTC Therapeutics has sold its rare pediatric disease priority review voucher (PRV) for $150 million, following FDA approval ...

Three of SUSL's underlying holdings with notable upside to their analyst target prices are CNH Industrial NV (Symbol: CNH), PTC Inc (Symbol: PTC), and Marathon Petroleum Corp. (Symbol: MPC).

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the global Phase 2 placebo-controlled CardinALS study did not meet its primary endpoint of slowing disease progression on the composite ...